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Abstract
Background: Multidrug-resistant tuberculosis (MDR-TB) in HIV endemic settings is a major threat to public health.
MDR-TB is a substantial and underreported problem in Sub-Saharan Africa (SSA), with recognised cases projected to
increase with advancement in diagnostic technology. There is paucity of review evidence on treatment outcomes
and antiretroviral (ART) uptake among MDR-TB patients with HIV in SSA. To address this gap a review of treatment
outcomes in HIV patients co-infected with MDR-TB in the SSA region was undertaken.
Methods: Three databases (Medline, Web of Science, CINHAL), Union on Lung Heath conference proceedings and
grey literature were searched for publications between January 2004 and May 2018. Records were assessed for
eligibility and data extracted. Random effect meta-analysis was conducted using STATA and Cochrane’s review
manager.
Results: A total of 271 publications were identified of which nine fulfilled the inclusion criteria. Data was collected
from 3368 MDR-TB and HIV co-infected patients from four SSA countries; South Africa (6), Lesotho (1), Botswana (1)
and Ethiopia (1). The most common outcome was cure (34.9% cured in the pooled analysis), this was followed by
death (18.1% in pooled analysis). ART uptake was high, at 83% in the pooled analysis. Cure ranged from 28.6 to
54.7% among patients on ART and from 22.2 to 57.7% among those not on ART medication. MDR-TB and HIV co-
infected patients were less likely to be successfully treated than HIV negative MDR-TB patients (Risk Ratio = 0.87,
95% CI 0.97, 0.96).
Conclusion: Treatment outcomes for MDR-TB and HIV co-infected patients do not vary widely from those reported
globally. However, treatment success was lower among HIV positive MDR-TB patients compared to HIV negative
MDR-TB patients. Prompt antiretroviral initiation and interventions to improve treatment adherence are necessary.
Keywords: Multidrug-resistant tuberculosis, MDR-TB and HIV co-infection, Treatment success, Unsuccessful
treatment, Sub Saharan Africa
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Background
Globally Tuberculosis (TB) remains a major cause of
death, with drug resistant forms resurging over the past
two decades [1]. Multidrug-resistant strains of TB (those
resistant to at least rifampicin and isoniazid) (MDR-TB)
have been associated with increased mortality and are a
particular issue among those living with the human
immunodeficiency virus (HIV) [2]. The 2017 Global TB
report estimated 10 million new TB cases, 1.6 million
deaths, with 0.3 million of these among those with HIV.
The burden is more concentrated in Sub Saharan Africa
(SSA) due to the high level of TB and HIV co-infection
in this region, with over 51% of TB cases co-infected
with HIV [3]. Globally, about 558,000 MDR-TB cases
were diagnosed in 2017, an increase from the 490,000
cases in 2016 [3, 4]. Among the 490,000 MDR-TB cases
in 2016, only 22% were initiated on treatment. Un-initi-
ated cases, the majority of which are reported from Af-
rica and Asia [4], constitute a significant reservoir of
infection in the community. Considering the synergy be-
tween HIV and TB infections in SSA, many un-initiated
MDR-TB cases will also be HIV coinfected [3].
Treatment provision for MDR-TB and HIV co-infection
has been scaled-up over the past decade but remains
below requirements in SSA [5]. This treatment gap
reflects a range of interconnected issues including the
complexity of MDR-TB, which includes long treatment
duration (24months) with large numbers of pills taken
daily, invasive daily intramuscular injections, side effects
due to drug toxicity [6] and complicities of the clinical
management of the co-infection. This results in high mor-
talities and poor treatment outcomes, a phenomenon that
has been described as the “perfect storm” [7, 8]. As a re-
sult of these complexities, there are a range of potential
treatment outcomes and these are usually classified into:
cure, treatment completed, death, treatment default, treat-
ment failure, transfer out and treatment success [9, 10].
To improve outcomes during treatment of MDR-TB and
HIV co-infection, the World Health Organization (WHO)
recommends concurrent treatment with second line anti-
tuberculosis drugs (SLD) and antiretroviral therapy
(ART), irrespective of CD4 cell counts [11]. Following its
roll out in SSA in 2004, ART has reduced mortality in
MDR-TB and HIV co-infected patients, yet HIV in MDR-
TB cases remains a significant predictor of death, with
complications in management of MDR-TB and HIV co-
infection leading to high mortality. Late ART initiation
and health system factors such as timely diagnosis of drug
resistance and lack of supportive financial systems have
partly been blamed for this observation [12].
Research on treatment outcomes in SSA has assessed:
the effect of ART initiation time on treatment outcomes
[13, 14], treatment success and survival in MDR-TB and
HIV co-infected cohorts [15–17] and predictors of
outcomes [14]. Previous reviews have addressed the risk
factors of HIV and MDR-TB in SSA [7, 18]. Yet, to date
no review on treatment outcomes in MDR-TB by HIV
status in SSA has been conducted. A global review on
TB treatment outcomes in adults and children [6] re-
ported no difference in treatment success between HIV
positive and negative MDR-TB patients. We speculate
that the finding in relation to HIV status may have been
diluted by low HIV prevalence in other regions. The
global review also included studies conducted prior to
rollout of ART in SSA. Therefore, we undertook a re-
view to investigate treatment outcomes for MDR-TB
and HIV co-infected patients in SSA in the era of HIV
ART to help inform policy, practice and research on the
treatment of MDR-TB and HIV co-infection in SSA.
Methods
This Prospero registered study (ID: CRD42018095600)
followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines.
Data sources
We searched Medline (EbscoHost), Web of Science Core
collections, CINAHL (EbscoHost) and Cochrane library
for articles published between January 2004 (2004 was
when roll out of ART across SSA started) and May
2018. The search strategy was modified from those used
by Samuels et al. [19] and Isaakidis et al. [6]. The follow-
ing Medical Subject Headings and free text terms were
used; Tuberculosis, Multidrug-Resistant Tuberculosis,
MDR-TB, HIV, Human Immunodeficiency Virus, People
living with HIV, PLWH, HIV/TB co-infection, drug re-
sistant tuberculosis/HIV coinfection, Multidrug resistant
tuberculosis HIV coinfection, Sub Saharan Africa, Africa
South of Sahara, Antiretroviral therapy, Antiretroviral
medication, Antiretroviral regimen, Antiretroviral ad-
ministration, Highly active antiretroviral, HAART, ART,
ARV, Treatment, Treatment outcome, Survival, Success,
Failure, default, cure, died, loss to follow up, treatment
completed (see Additional file 7).
To identify studies only in grey literature, abstracts
submitted to the annual conference of the International
Journal of Tuberculosis and Lung disease (IJTLD) from
2005 to 2017 were manually searched. Authors whose
abstracts matched inclusion criteria were contacted via
e-mail for additional data. Annual reports and publica-
tions by Medecins Sans Frontieres, WHO, United
Nations Joint Commission on HIV/AIDS (UNAIDS) and
US Presidents Emergency Plan for AIDS Relief (PEP-
FAR) were also searched.
Inclusion criteria
Included studies fulfilled the following characteristics: 1)
Included culture or drug susceptibility testing confirmed
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MDR-TB patients 2) clearly reported the use of either
individualized, standardized or mixed MDR-TB treat-
ment regimen, 3) reported the use of ART during the
treatment of MDR-TB and HIV co-infection 4) reported
at least one of the six outcomes recommended by Learson
et al and WHO [9, 10], 5) documented a minimal age of
15 years for study participants, 6) conducted between
January 2004 when ART roll out started to May 2018
(with the exception of studies that compared MDR-TB,
and MDR-TB and HIV co-infected patients that began
with collection of MDR-TB data earlier than 2004 and
subsequently incorporated MDR-TB and HIV co-infec-
tion data from 2004), and 7) conducted in SSA, and
published in English.
Study selection
After exhaustive database, bibliographic and manual
searching, retrieved studies were screened with dupli-
cates removed using the EndNote X8 reference manage-
ment software. Publication titles and abstracts were
initially screened, and non-relevant ones excluded. The
full text of retained studies were read and those that did
not match inclusion criteria were excluded with justifica-
tion. Study quality and risk of bias in reporting findings
was assessed. Two authors (EDC) and (VH) independ-
ently conducted article and abstract screening, while the
third author (MCVH) validated these. Disagreements on
articles to include/exclude were resolved through
consensus.
Data extraction
We extracted data using a data extraction form, de-
signed in Microsoft Excel based on those used in other
reviews and piloted on five studies. Data was extracted
by one author and checked by another. In cases of dis-
agreement, a consensus was reached among all authors.
Key data extracted for each study include: year of publica-
tion, study design, study country, study description, sample
size, participant age, number with confirmed MDR-TB and
HIV co-infection, number with MDR-TB, number on ART
& time of initiation on ART, type of MDR-TB regimen,
MDR-TB treatment duration, treatment setting (centralised
hospital-based treatment or decentralised community,
clinic and hospital- based treatment), treatment outcomes,
and predictors of MDR-TB treatment failure and mortality
(see Additional file 8).
Quality assessment
Cohort and case control studies were assessed for quality
using the Newcastle-Ottawa quality assessment scale
[20] and the randomized control trial using the National
Institute of Health (NIH), quality assessment tool for
controlled intervention studies [21]. Indicators of good
study quality captured by both tools were; use of
standardized method to confirm MDR-TB and HIV
status; large sample size with a cut off value of at least
40 participants; multicentre study; integration of home,
clinic and hospital based care; use of appropriate statis-
tical tests to classify and report outcomes; taking
confounders (demographics, socioeconomic status, pre-
vious treatment history) into account during data
analysis; clear method of participant selection; and rep-
resentativeness of study participants to the population of
MDR-TB and HIV co-infected population. In addition,
use of a valid source for retrieving outcomes and partici-
pant information; adequate treatment duration; report-
ing less than 1/3 missing data at final analysis compared
to original population recruited, and proof of ethical
review of the study were also considered.
Treatment outcomes were recorded following the
proposal by Learson et al [9] and WHO [10] defini-
tions (see Additional file 1).
Data analysis and synthesis
STATA 13.1 (Statacorp) and Review manager version
5.3 were used for meta-analysis. Heterogeneity among
studies was evaluated at 95% confidence level using bin-
ary effect analysis. To facilitate analysis and enable com-
putation of dichotomous effect measures, outcomes
were grouped into two categories; treatment success
(cure and competed treatment) and unsuccessful treat-
ment (death, defaulted, lost to follow up, failure). Studies
were included in the analysis based on outcomes re-
ported. A sub-group analysis for treatment success and
unsuccessful treatment in those with MDR-TB accord-
ing to HIV status was conducted using the Mantel-
Haensel random effects method. Heterogeneity of binary
covariates was estimated using I2 and P values, at 95%
confidence level.
Results
Database searches identified 314 articles and 33 records
were obtained from additional sources (all from the ab-
stract books of the annual World Conference on Lung
Health). Requests for additional data were sent to two
authors and one responded. Following deduplication,
there were 271 unique records. Titles and abstracts were
screened excluding 237 of these. Full text of the
remaining 34 were assessed, 25 were excluded (Fig. 1).
Nine studies were thus included in this review.
Study characteristics
The nine studies were published between 2012 and
2018. Their sample sizes ranged from 23 to 1137
(mean = 580) and they had a total of 4666 participants.
Of these, 3368 were MDR-TB and HIV co-infected.
Study duration varied from one year [13] to over eight
years [16], with majority (n = 4) of the studies conducted
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over periods of three to four years [14, 22–24]. Six stud-
ies were conducted in South Africa [14, 16, 22–25], one
in Lesotho [13], one in Botswana [17] and one in
Ethiopia [15]. Five studies were retrospective cohort
studies [13–16, 24], with two prospective cohort studies
[17, 22], one case control study [23] and one random-
ized controlled trial (RCT) [25]. Six studies reported
treatment for pulmonary and extra-pulmonary tuber-
culosis [13–15, 22, 24, 25]. However, three studies did
not specify the type of MDR-TB treated [16, 17, 23].
Six studies were conducted in centralised MDR-TB
treatment settings [14, 16, 22–25], while three were
in a decentralised treatment setting [13, 15, 17]. Not
all studies reported the type of anti-tuberculosis drug
[16, 25] and ART used [14, 16, 17, 24] during treatment
of MDR-TB and HIV co-infection. Treatment duration
and follow-up for MDR-TB and HIV co-infected patients
within the studies ranged between 18 and 24months (see
Additional file 2).
Treatment outcomes
Cure was the most common outcome reported, ranging
from 26.1 to 68% across the studies, with a pooled pro-
portion cured 34.9% (see Additional file 3). One study
reported the combined outcome for cure and completed
treatment [16]. Deaths were the second most common
outcome, pooled proportion 18.1%, study range 11.2 to
34.3%. Default was reported in six studies and ranged
Fig. 1 PRISMA flow chart illustrating selection of included studies from SSA on MDR-TB treatment in those with MDR-TB and HIV coinfection.
*Reports and publications from World Health Organisation, Medecin Sans Frontieres, UNIAIDS, PEPFAR
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from 1 to 22.3%. The least commonly reported outcome
was still being on treatment at the end of follow-up
(see Additional file 4).
ART uptake and treatment success
Approximately half of the HIV positive MDR-TB pa-
tients in each study were already on ART prior to
MDR-TB treatment initiation (see Additional file 5).
The overall proportion of MDR-TB and HIV positive
patients on ART was high except in two studies [16, 23],
pooled proportion 83% (see Additional file 6). Treatment
success varied between HIV negative and positive MDR-
TB patients, with higher rates in HIV negative patients, in
all but one study [13]. Unsuccessful treatment in contrast
was higher among HIV positive cases compared to HIV
negative cases in five studies [15–17, 22, 24], but was
lower in one study [13]. The ratio of treatment success to
unsuccessful treatment was about 2:1 among HIV positive
patients and 3:1 among HIV negative patients (see
Additional file 5). The pooled risk ratio for successful
MDR-TB treatment in HIV positive versus HIV nega-
tive patients was 0.87 (95% CI, 0.79, 0.96) (Fig. 2).
Cure according to ART status
Uptake of ART for HIV did not affect the proportion
whose MDR-TB was cured among the MDR-TB and
HIV co-infected patients. Cure outcomes ranged from;
28.6 to 54.7% among patients on ART, and from 22.2 to
57.7% among those not on ART medication (Table 1).
Discussion
This review identified nine studies, reporting data on
treatment of MDR-TB among those living with HIV in
SSA. The most frequently reported outcome for MDR-
TB was cure, followed by death and the least commonly
reported outcome was still being on treatment for
MDR-TB. Overall, HIV ART uptake was high among
those MDR-TB patients living with HIV, however MDR-
TB treatment was still less successful among this group
than among those not HIV co-infected.
The most common MDR-TB treatment outcome
among the MDR-TB and HIV co-infected patients was
cure (pooled proportion 34.9%). This is higher than the
reported proportion cured (16%) among MDR-TB and
HIV co-infected patients in WHO region Europe [26].
The low cure proportion in the WHO region Europe,
could be attributed to the variation in quality of MDR-
TB and HIV treatment services within different parts of
Europe, with patients in Eastern Europe more likely to
receive empiric anti-TB treatment with reduced activity
compared to other parts of Europe. There were also
only a small number of MDR-TB and HIV patients
involved in the study which might have skewed the out-
come [27, 28]. In addition, the HIV epidemic in Europe
is a concentrated one, focused on higher risk groups
including people who inject drugs, whilst that in SSA is
as generalised epidemic.
High levels of death and default accounted for unsuc-
cessful outcomes in this study. Unsuccessful treatment
was higher in MDR-TB patients living with HIV than in
other MDR-TB patients. Poorer treatment outcomes
Fig. 2 Forest plot of studies that quantitatively assessed the association between treatment success and HIV status among MDR-TB patients in
SSA. CI = Confidence Interval MH =Mantel Hansel test
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have also been reported in a review of outcomes among
MDR-TB patients living with HIV and other comorbidi-
ties [19]. These findings indicate the need for increased
efforts to improve management of MDR-TB and HIV
co-infection, such as, active case holding for immedi-
ate initiation on therapy and active mechanisms for
tracing those who default. However, higher levels of
unsuccessful treatment among MDR-TB patients with
HIV compared to those without HIV observed in this
study, contradicts the findings from previous reviews
that report similar levels of MDR-TB treatment suc-
cess in both groups [6, 7]. These reviews included
studies from settings with a low prevalence of HIV
which might have impacted their overall findings
related to effect of HIV status.
Observed mortality was high in this review at 18.1%
(studies ranging from 11.2 to 34.3%), whilst lower than
38% pooled mortality in a similar global review on adults
and children [6], it was higher than the 12% mortality
reported in the WHO region Europe [26] and 11% in a
review on impact of ART on mortality among TB and
HIV patients [29]. A lower mortality than the global
review could be due to high ART uptake in the studies
included in our review, however higher mortality than
that reported in the other two reviews may be related to
differences in the populations affected and regional dif-
ferences in the epidemiology of HIV and MDR-TB.
In this review, the pooled proportion of patients who
defaulted was 6.8%. This was lower than 16.1% [6]
reported in a previous review. Worst outcomes in the
previous review were reported among early cohorts prior
to ART roll out when the use of ART was limited. In
addition, some studies in our review did not report
default outcomes [15, 17, 25] which might have affected
the pooled value.
Though centralised treatment settings have been
praised for their high treatment retention and low levels
of default [30], the higher levels of defaults in this review
were identified in studies in centralised settings. How-
ever, a review by Weiss et al [31] demonstrated no dif-
ference in outcome between treatment settings. More
investigations are required to understand program
related characteristics in both settings that might have
produced this observation.
The uptake of ART among those living with HIV
increased during the course of MDR-TB treatment, from
approximately 50% uptake prior to treatment to an over-
all pooled uptake of 83% (0.83). Progressive increase in
ART uptake during MDR-TB and HIV co-infection
treatment, illustrates active implementation of the WHO
recommendation for concurrent treatment in MDR-TB
and HIV co-infection [11, 22]. ART uptake in this review
is high compared to an uptake of 67% among MDR-TB
and HIV co-infected patients in Eastern Europe. This is
attributed to the weak implementation of concurrent
treatment in Eastern Europe, following a rise in HIV
prevalence [32].
Ideally, we would expect high ART uptake to improve
treatment outcomes for MDR-TB and HIV co-infected
patients. This was not the case in this study. Poor adher-
ence to ART and the complication in the management of
MDR-TB and HIV co-infection maybe responsible [14,
33]. In addition to opportunistic infections, most MDR-
TB and HIV co-infected patients included in retained
studies, reported low CD4 cells < 100 cells/mm3, being se-
verely underweight and having chest cavity lesions at base-
line [15, 17]. Patients with CD4 counts < 100 cells/mm3
are more likely to die after starting treatment [14, 23].
Therefore, the poor outcomes observed in this proportion
of patients may not be attributed solely to the ineffective-
ness of the treatment program but partially to the baseline
characteristic of these patients prior to treatment.
Limitation
Our review has a number of limitations. We assumed
that patients who default therapy or who are lost to fol-
low-up during TB treatment, will have done so because
they were experiencing poor outcomes. Therefore,
default, lost to follow up, on treatment and transfer out,
were classified into unsuccessful treatment in the ana-
lysis. One study had children aged under 15 years nested
within the study population [23]. However, there were
only 7 MDR-TB and HIV co-infected children within
the 363 participants. We assumed their effect on the
Table 1 Cure rates for MDR-TB and HIV coinfected patients in SSA by ART status
Author and year On ART No ART
Cured (%) Not cured (%) Cured (%) Not cured (%)
Umanah et al 2015 [14] 312 (32.9) 635 (67.1) NR NR
Van der Walt et al 2016 [16] 52 (54.7) 43 (45.3) 172 (57.7) 126 (42.3)
Mugabo et al 2015 [23] 19 (35) 35 (65) 14 (34) 27 (66)
Padayatchi et al 2014 [25] 4 (28.6) 10 (71.4) 2 (22.2) 7 (77.8)
Umanah et al 2015b [24] 339 (29.8) 798 (70.2) NR NR
NR Not reported.
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analysis was negligible. One study had a sample size of
23 participants [25], this randomised control trial had
methodological shortcomings and was rated as poor
quality. This study was dropped from subgroup ana-
lysis of MDR-TB patients according to HIV status.
However data from this study was included in the
tables, and in the forest plots on treatment outcomes
and proportion of ART uptake, so as to present the
contribution of each study. Inclusion of this study
generated high heterogeneity scores. There were
limited data to examine the impact of ART uptake
among MDR-TB patients living with HIV, this prob-
ably reflecting WHO recommendations [11] for
concurrent treatment for all co-infected patients. This
limited our ability to investigate the impact of ART
on MDR-TB treatment outcomes. Not all studies pro-
vided data on all items of interest which could lead
to bias. Eight of nine studies were from Southern
African (Bostwana, Lesotho and South Africa) and
one was from East Africa (Ethiopia), possibly reflect-
ing this review only including studies published in
English. The findings should therefore, only be gener-
alised to the entire SSA region with caution.
The paucity of data from outside of southern Africa is a
concern and may reflect limited research resources avail-
able among west, central and east African countries. Lack
of infrastructure, equipment, human resources and ab-
sence of good health information system [5, 18] in TB
programs have been advanced as reasons for paucity in
MDR-TB data and studies conducted in SSA. The number
of publications on treatment outcomes for MDR-TB and
HIV coinfection in SSA are low and the quality of studies
is generally weak when compared to those in similar glo-
bal reviews [6, 18, 32]. This reiterates the need for more
research in SSA region.
Conclusion
Despite endemicity of HIV in SSA, treatment outcomes
for MDR-TB and HIV co-infected patients on ART do
not vary widely from those reported globally. However,
treatment success rates are lower in HIV positive patients
compared to HIV negative patients. This is probably due
to high levels of deaths and defaults in HIV positive pa-
tients. ART uptake was high with progressive increase in
uptake as MDR-TB and HIV treatment advances. Unsuc-
cessful treatment outcome and low cure rates in patients
on ART most probably reflect poor adherence to therapy.
Emphasis should be laid on prompt initiation, support of
patients, and ART adherence, to reduce the debilitating ef-
fect of low CD4 counts and opportunistic infections that
may increase chances of death and other unfavourable
outcomes. These findings indicate that the DOTS plus
strategy should be strengthened alongside scaling up of
integrated decentralized treatment strategies.
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